Overall, our in vivo studies depleting CD4+ T cells and employing the CXCR3-blocking Ab highlight infiltration of CXCR3-expressing T cells as a potential mechanism that contributes to tumor regression in the context of this combination therapy. The gene discussed is CXCR3; the disease is neoplasm.